ClinicalTrials.gg

Program

Alfentanil

Its studies are mostly in Chronic Pain, led by Sichuan Kelun Pharmaceutical.

Furthest: phase 1, since Jul 5, 20261 company-led study, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Kelun Pharmaceutical10 open or runningphase 1since Jul 5, 2026Jul 5, 2026none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 5, 2026First study: phase 1 study in Chronic PainFirst studyNCT07710560 · 27 enrolled · China

TargetBeta

OPRM1 →read by rule
“Mu opioid receptor agonist”ChEMBL 37, by rule

Other programs on OPRM1

ProgramCompanyFurthest phaseStudies
OxycodoneruleMundipharmaphase 472
Naltrexoneruleorexigen-therapeutics-incphase 442
nalmefeneruleH. Lundbeckphase 420
NalbuphineruleTrevi Therapeuticsphase 420
MethadoneruleMerckphase 416
cebranopadolruleTris Pharmaphase 318
axelopranruleglycyx-therapeuticsphase 28

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07710560Chronic Pain · China1CompletedAug 12, 202627

How it is read

Names in the registry

  • “Alfentanil Hydrochloride Injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.